Glide Pharma signs biologicals deal with major pharma company
28-Feb-2008
The deal is described as a future-directed relationship, focusing initially on one of the pharma company's branded biologicals; the new partner has also taken an option to enter into a full development programme. Under the terms of the deal, Glide Pharma will develop and test a range of solid dosage formulations of the branded peptide in the unique Glide SDI. These formulations will then be supplied to the partner company for further evaluation.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
List_of_hesperiid_genera:V
Go to page
List_of_Apiaceae_genera
Go to page
Bethanechol
Go to page
Celsius® FFT|FFTp Bags | Deep-freeze containers | Sartorius
Go to page
Intercell AG appoints Staph Leavenworth Bakali as Chief Business Officer
Go to page
List_of_crambid_genera:_M
Go to page
FSP-Tech GmbH - Essen, Germany
Go to page
Biofrontera raised 3 Million Euro in capital round
Go to page
First clinical trial for the Parkinson´s vaccine starts in Vienna
Go to page